In adults and children undergoing renal transplantation, does dose individualisation of Mycophenolate Mofetil based on a pre-transplant free MPA pharmacokinetic assessment improve post-transplant drug exposure, compared to post transplant exposure on standard fixed doses - as assessed by an increased proportion of patients within therapeutic range from early (day 3-5) post transplant in the dose individualised group, and again at 2 weeks and 3 months post transplant.